Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial ...

At week 40, the change from baseline in HbA1c was −1.44 and −0.67 percent with tirzepatide and dulaglutide escalation to 4.5 mg or maximum tolerated dose, respectively. HealthDay News — For patients ...

In 2020, the FDA granted approval for two higher doses of dulaglutide, namely 3.0 mg and 4.5 mg. This approval was based on the results of the AWARD-11 trial, which demonstrated the improved ...

A new study published in Cardiovascular Diabetology suggests that in all of the placebo-controlled studies conducted as part of the AWARD program, dulaglutide 1.5 mg decreased systolic blood pressure ...

Patients with type 2 diabetes who receive dulaglutide therapy are likely to experience weight-dependent and –independent effects on blood pressure. Dulaglutide 1.5 mg shows both a weight reduction ...

USA: Findings from a post-analysis of the AWARD-11 study have suggested similar favorable effects of dulaglutide 3.0 mg and 4.5 mg on several cardiometabolic CVD risk factors, if not greater than ...

The groups examined were placebo (n=51), 0.75 mg (n=51), and 1.5 mg (n=52) weekly. At 26 weeks, the pooled dulaglutide group had a mean glycated hemoglobin 0.8 percent less than baseline, compared to ...

About 3 times as many of the children and teenagers taking dulaglutide had a glycated hemoglobin level of less than 7.0% at 26 weeks compared with those on placebo. Treatment with a once-weekly ...

For participants who were randomly assigned to receive the 1.5-mg dose, dulaglutide was initiated at the 0.75-mg dose for the first 4 weeks and then escalated to the 1.5-mg dose if the participant ...

Type 2 Diabetes Researchers conducted an indirect treatment comparison of semaglutide 2.0 mg with dulaglutide 3.0 mg or 4.5 mg to observe which was superior in lowering HbA1c and body weight in people ...